Top 50 Medical VC (Venture Capital) Funds in Oceania in January 2026

Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.

Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Giant Leap is Australia's first venture capital fund to be 100% dedicated to investing in exceptional, rapidly scalable impact businesses.

Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.

We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Right Click Capital - Australian Venture Capital Firm

Founded by Steve Baxter, Transition Level Investments provides equity capital and operational expertise across Seed and Series A rounds to Australian companies. Our team focuses on a company-growth approach, adding value by assisting founders to build their expertise, expand their team, build product, scale locally and globally to position for asuccessful exit. We have a track record of identifying investment opportunities in the Australian market and helping enable global growth.

Icehouse Ventures is an early-stage venture capital firm. We exist to back the world's bravest Kiwi founders, launching global companies from New Zealand.

Clinton Capital Partners is a VC advisory business that specialises in raising capital and growing shareholder returns, for early stage technology companies and their investors. In addition, we invest our own funds to align company, investor and advisor. We have completed >70 successful transactions, and crystallised 14 liquidity events.Clinton Capital Partners has a long and established track record of growing companies, raising capital, conducting mergers, and creating liquidity events. When raising capital, we feel early-stage companies underestimate the time involved, the distraction to the underlying business, and the importance of identifying the “right culturally aligned” investors for their journey.

Larsen Ventures is a lean, driven and strategic venture investment firmWe believe in alignment, long-term thinking & investor due diligence
 We like metrics, traction & perseverance
 We invest in people
1/3 of our focus is on Health and Education; 
We like the thematic & overall gains for society2/3 of our time is spentlearning from peers, digging into research, 
chasing leads & hanging out on caffeinated zooms in the endless search for;Founders with Traction 
Founders with Insight
 Founders with Perseverance and Courage 
Founders with an innate ability to question EverythingWe have patient capital that engages & contributes to your Journey 
Accelerate your business with our portfolios' intellectual capital

Blackbird is a venture capital fund based in Australia and New Zealand. We invest in every type of technology from software to space, unified by the biggest of ambitions.

Resource Capital Funds is a mining-focused alternative investments firm that partners with companies to build strong, successful, and sustainable businesses.

EVP is an early stage venture capital firm based in Sydney Australia with c. $300M FUM across four fund vintages.Our most recent fund was launched in December 2022 and is a $100M fund. The fund targets early Series-A investments initially with cheque sizes in the range of $0.5 – $5.0 million. Our funds invest in software, are sector agnosticand have a focus on Australian based B2B SaaS companies.Over the years, we’ve backed brilliant founders building global software companies like SiteMinder, Deputy, Ignition and Shippit. We make high conviction investments, underpinned by ambition, pragmatism and a deep understanding of the software journey.

Regal Funds Management was founded in 2004 by Andrew and Philip King. Regal utilises a long/short investment strategy and performs investment management and investment advisory services to a number of Australian Unit Trusts and Cayman Island Companies.

Investing in scalable science and deep tech start-ups in Aotearoa NZ. We operate venture capital funds that invest in science and deep tech through a hands-on, active approach.

Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.

Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.

Investing in great people solving hard problems to create a better future.

Carthona Capital is a hands-on, proactive, and thematic venture capital investor based in Sydney, Australia that invests globally.

Tyson & Blake We identify growth companies with unique approaches and innovative technologies that have the potential to make a profound contribution to society.We develop inspiring businesses that share our goals and our values.We create a positive impact and long-term value for our investors, the companies we invest in and the communitieswe live in.

Connecting startup business owners with angel investors to raise capital . Access a network of expertise and investment opportunities.

Privately Held Companies

FundWA is a Western Australian venture capital fund that invests in technology-enabled innovative businesses in Western Australia.

Join our leading Australian superannuation fund, committed to putting our members first, with a low admin fee and strong returns. Become a member today!

Investing in the deep science and technology that can propel humanity towards a radically better future.

Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.

Purpose Ventures is a Venture Capital Fund in Perth Western Australia backing the next generation of entrepreneurs and innovators.

Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!

Medical Angels is the premier medical and health-specific angel investment syndicate, comprised of over 1,000 clinicians from across Australia.

Black Sheep Capital is making its mark as a preferred investment capital provider due to their 'Everyone Wins' approach. Their philosophy is to work with their investment partners to create and grow opportunities where they can all enjoy success. Through this approach, they have been able to create a diverse portfolio of investments thatcontinues to grow.

OIF is a venture capital firm focusing on partnering with entrepreneurs building businesses.

Prtnr is an investment firm.

Salus Ventures is a venture capital firm.

Telstra Ventures provide venture capital investment in lighthouse technology companies that are commencing scale. Leveraging data science for scaling new business.

Championing the next generation of B2B technology startups.

Scalare Partners is more than a technology investment fund. We provide critical funding and resourcing

Auckland University's commercialisation arm

The New Zealand Growth Capital Partners (formerly New Zealand Venture Investment Fund) was established to support early-stage technology companies and to stimulate private investment into this space.

Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology in Australia, New Zealand, Southeast Asia and globally.

Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.

At UniServices, we partner with the University of Auckland to transform ideas into real-world solutions that impact globally.

A multi-stage investment fund focused on Consumer, Enterprise, Fintech, Frontier, Healthcare, & PropTech

Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under managementand focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.

HTC Corp is engaged in the design, development, and manufacture of smartphones and tablets in Taiwan.The company offers PDA phones and smartphones for mobile operators and distributors in Europe, the United States, and Asia. These machines are available as HTC devices and as products individually customized for operators and device partners.The company provides its own HTC self-branded products as well as supports operator-branded products and original equipment manufacturer (OEM) partners. It owns Dopod as a subsidiary company and is a member of the Open Handset Alliance.The company’s products are sold under various brand names such as HTC, Dopod, and Qtek and are often rebranded by major telecommunication carriers. Its products also include pocket PC phones (PDA Phone), ultra mobile phones, HTC kovsky (Sony Ericsson XPERIA X1), and HTC dream (T-mobile G1).HTC Corp was founded by Cher Wang and Peter Chou in 1997. It is headquartered in New Taipei City, Taiwan.

Queensland Investment Corporation is an investment company.

Jelix is an early-stage venture capital firm backing daring founders in Australia and New Zealand.